Literature DB >> 24724929

Is the PANSS cognitive scale measuring cognition?

René Ernst Nielsen1, Eva Lindström, Gry Kjærsdam Telléus, Sten Levander.   

Abstract

OBJECTIVE: To investigate the association between the Positive and Negative Syndrome Scale (PANSS) cognitive factors and cognition assessed by neuropsychological tests.
METHOD: Ninety patients with a psychotic illness, the majority having a schizophrenia diagnosis, were assessed with PANSS ratings and tested by a comprehensive computerized neuropsychological test battery, EuCog.
RESULTS: Test performance was in the normal range for some of the cognitive indices, but substantially reduced for others, compared with norms, particularly speed-based indices. PANSS ratings were non-specifically associated with cognitive indices representing performance (speed and accuracy) and problem solving strategies (executive functions). There was no discriminant validity for the cognitive factor. A regression analysis suggested that the PANSS cognitive factors reflected verbal IQ but no other cognitive domain like memory, attention or speed.
CONCLUSION: Cognitive test performance is associated with psychopathology as assessed by PANSS items but in a non-specific way. The PANSS cognitive subscale seems to reflect over-learned verbal skills rather than the cognitive domains, which are known to be specifically affected in schizophrenia and relevant for the prognosis. Consequently, PANSS ratings cannot replace the information inherent in neuropsychological test data. The extensive speed problem of patients with schizophrenia should be studied in more detail using test batteries that focus on that problem.

Entities:  

Keywords:  Cognition; Neuropsychology; Schizophrenia

Mesh:

Year:  2014        PMID: 24724929     DOI: 10.3109/08039488.2014.898790

Source DB:  PubMed          Journal:  Nord J Psychiatry        ISSN: 0803-9488            Impact factor:   2.202


  3 in total

1.  Inflammation in individuals with schizophrenia - Implications for neurocognition and daily function.

Authors:  Sophia Kogan; Luz H Ospina; David Kimhy
Journal:  Brain Behav Immun       Date:  2018-09-12       Impact factor: 7.217

2.  Matrix Metalloproteinase 9 Blood Alterations in Patients With Schizophrenia Spectrum Disorders: A Systematic Review and Meta-Analysis.

Authors:  Georgios Schoretsanitis; Renato de Filippis; Maria Ntogka; Stefan Leucht; Christoph U Correll; John M Kane
Journal:  Schizophr Bull       Date:  2021-07-08       Impact factor: 9.306

3.  Combination of Electroconvulsive Therapy and Clozapine in Treatment-Resistant Schizophrenia.

Authors:  Jung Hyun Kim; Tak Youn; Jun Gwon Choi; Seong Hoon Jeong; Hee Yeon Jung; Yong Sik Kim; In Won Chung
Journal:  Psychiatry Investig       Date:  2018-08-09       Impact factor: 2.505

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.